Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13,691Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-11.0EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.6Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.710-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.5PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M100,000,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVKen Fisher 2016-03-31 Add$63.52 - $72.03
($67.02)
$ 74.9312%Add 1.75%298,675
XLVKen Fisher 2015-12-31 Add$66.86 - $72.99
($70.76)
$ 74.936%Add 2.64%293,541
XLVKen Fisher 2015-09-30 Add$64.29 - $77.22
($73.06)
$ 74.933%Add 5.33%285,985
XLVLeon Cooperman 2015-06-30 Sold Out -0.42%$71.46 - $76.45
($73.85)
$ 74.931%Sold Out0
XLVKen Fisher 2015-06-30 Add$71.71 - $76.45
($74.07)
$ 74.931%Add 5.40%271,515
XLVLeon Cooperman 2015-03-31 Buy 0.42%$67.86 - $74.9
($71.15)
$ 74.935%New holding366,000
XLVKen Fisher 2015-03-31 Add$68.05 - $74.9
($71.32)
$ 74.935%Add 4.15%257,614
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 74.9328%Add 34.36%226,412
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 74.9393%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 74.93103%New holding50,000
XLVKen Fisher 2012-06-30 Add$35.52 - $37.87
($36.91)
$ 74.93103%Add 53.52%119,754
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 74.93114%New holding86,997
XLVGeorge Soros 2011-03-31 Sold Out $31.5 - $33.18
($32.33)
$ 74.93132%Sold Out0
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 74.93141%Reduce -93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 74.93157%New holding558,053
XLVGeorge Soros 2010-06-30 Sold Out $28.38 - $32.31
($30.13)
$ 74.93149%Sold Out0
XLVGeorge Soros 2010-03-31 Reduce$30.68 - $33
($31.72)
$ 74.93136%Reduce -43.59%6,600
XLVGeorge Soros 2009-12-31 Buy 0.01%$28.07 - $31.62
($30.04)
$ 74.93149%New holding11,700
XLVBill Gates 2009-06-30 Sold Out -4.19%$23.76 - $26.53
($25.04)
$ 74.93199%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Honig, BarryDirector 2016-07-08Buy20,000$0.3124032.26view
Nadeau, SteveSenior Officer 2016-07-08Buy4,500$1.245933.06view
haukedal, peter lawrence10% Security Holder 2016-07-08Buy41,000$0.07106771.43view
haukedal, peter lawrence10% Security Holder 2016-07-08Buy9,000$0.07106771.43view
Roodenburg, Anthony RalphDirector, Senior Officer 2016-07-08Buy100,000$0.1549773.33view
Churcher, Dale LeeworthySenior Officer 2016-07-08Sell39,377$6.551042.14view
Sanderson, Robert KeithDirector 2016-07-08Buy15,000$0.04186925view
International Finance Corporat10% Security Holder 2016-07-08Sell1,000,000$0.05149520view
Meade, Harlan DonnleyDirector, Senior Officer 2016-07-08Buy1,500$0.1646656.25view
Meade, Harlan DonnleyDirector, Senior Officer 2016-07-08Buy4,000$0.1841461.11view

Quarterly/Annual Reports about XLV:

    News about XLV:

    Articles On GuruFocus.com
    S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
    Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    Biogen Misses EndPoints in Synergy Trial for Opicinumab Jul 27 2016
    What Is Johnson & Johnson’s Valuation? Jul 27 2016
    What to Expect from Becton, Dickinson and Company in Fiscal 3Q16 Jul 27 2016
    Is Zimmer Biomet Expected to Post Revenue Growth for 2Q16? Jul 27 2016
    Edwards Lifesciences’ 2Q16 Earnings Surpass Analyst Estimates Jul 27 2016
    Analysts’ Take on Zimmer Biomet Holdings before 2Q16 Earnings Jul 26 2016
    Buy Express Scripts at $73, Not Near $77 Jul 26 2016
    What’s Boosted Investors’ Confidence in Biogen in 2016? Jul 26 2016
    Thermo Fisher Scientific’s 2Q16 Revenues: What’s in Store? Jul 25 2016
    Sector Flows: Should Equity Bulls Be Worried? Jul 25 2016
    The Zacks Analyst Blog Highlights: Health Care Select Sector SPDR Fund, iShares U.S. Consumer... Jul 25 2016
    Orkambi Launch Impacts Vertex Pharmaceuticals’s Major Revenue Contributor Jul 25 2016
    GILD Developing Next Generation HCV Drugs to Remain Competitive Jul 22 2016
    St. Jude Medical Gets ‘Hold’ Rating from 96% of Analysts Jul 22 2016
    Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks? Jul 22 2016
    How Alexion Plans to Fuel Strensiq Sales Jul 22 2016
    Why Johnson & Johnson’s 2Q16 Profits Fell by 11.5% Jul 22 2016
    What Are Lilly’s 2Q16 Estimates and Expectations for Elanco? Jul 22 2016
    Abbott’s 2Q16 Earnings Propelled by Impressive Sales Growth Jul 22 2016
    Summer's top summer sector: Health care Jul 22 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)